Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 17 January 2014 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) is seeking new industry members industry to serve on two of its medical device-focused advisory committees, it announced today.
In a 17 January 2014 announcement in the Federal Register, FDA said it is soliciting nominations for both the Medical Devices Advisory Committee (MDAC) and three of MDAC's more specific panels: the Dental Products Panel, the Hematology and Pathology Devices Panel, and the Immunology Devices Panel.
In a separate notice, FDA also said it is seeking non-voting industry representatives to serve on its Device Good Manufacturing Practice Advisory Committee (DGMPAC), which makes recommendations on device manufacturing, distribution and use issues.
"Persons nominated for the [MDAC] should be full-time employees of firms that manufacture products that would come before the panel, or consulting firms that represent manufacturers, or have similar appropriate ties to industry," FDA wrote in the Register notice.
For the DGMPAC, nominated persons need only "possess appropriate qualifications to understand and contribute to the committee's work as described in the DGMPAC's function," regardless of their ties to industry.
Individuals may self-nominate themselves for the advisory committee. Organizations, too, may nominate candidates or groups of candidates.
Companies interested in the selection process should, within 30 days, send a letter of interest to FDA. After 30 days, FDA will compile a list of all nominated persons and send that list to organizations which have expressed interest. The organizations will then need to collectively select a candidate to serve on the MDAC and its panels within 60 days. Failure to select a nominee will result in FDA choosing one on behalf of industry.
All selected persons would serve in a non-voting, advisory capacity.
Federal Register Notice: MDAC
Federal Register Notice: DGMPAC
Regulatory Focus newsletters
All the biggest regulatory news and happenings.